NASDAQ:BLCM Bellicum Pharmaceuticals - BLCM Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Bellicum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.18 -0.06 (-4.84%) (As of 02/2/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.16▼$1.2550-Day Range$0.65▼$1.4852-Week Range$0.60▼$2.20Volume29,654 shsAverage Volume67,639 shsMarket Capitalization$10.16 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Bellicum Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside323.7% Upside$5.00 Price TargetShort InterestHealthy1.06% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.78Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.54) to ($1.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.45 out of 5 stars 3.5 Analyst's Opinion Consensus RatingBellicum Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, Bellicum Pharmaceuticals has a forecasted upside of 323.7% from its current price of $1.18.Amount of Analyst CoverageBellicum Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.06% of the float of Bellicum Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverBellicum Pharmaceuticals has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bellicum Pharmaceuticals has recently decreased by 10.36%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBellicum Pharmaceuticals does not currently pay a dividend.Dividend GrowthBellicum Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLCM. Previous Next 3.2 News and Social Media Coverage News SentimentBellicum Pharmaceuticals has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Bellicum Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest3 people have searched for BLCM on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Bellicum Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bellicum Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders10.30% of the stock of Bellicum Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 28.66% of the stock of Bellicum Pharmaceuticals is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Bellicum Pharmaceuticals are expected to grow in the coming year, from ($1.54) to ($1.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bellicum Pharmaceuticals is -2.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bellicum Pharmaceuticals is -2.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBellicum Pharmaceuticals has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Bellicum Pharmaceuticals (NASDAQ:BLCM) StockBellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.Read More Receive BLCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bellicum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address BLCM Stock News HeadlinesFebruary 2, 2023 | americanbankingnews.comBellicum Pharmaceuticals (NASDAQ:BLCM) Coverage Initiated at StockNews.comJanuary 31, 2023 | finance.yahoo.comCORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 3, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 25, 2023 | americanbankingnews.comBellicum Pharmaceuticals (NASDAQ:BLCM) Receives New Coverage from Analysts at StockNews.comJanuary 19, 2023 | finance.yahoo.comBellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers SymposiumNovember 13, 2022 | finanznachrichten.deBellicum Pharmaceuticals, Inc.: Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational UpdateNovember 10, 2022 | finance.yahoo.comBellicum Reports Third Quarter 2022 Financial Results and Provides Operational UpdateOctober 4, 2022 | finance.yahoo.comBellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the MesaFebruary 3, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.September 15, 2022 | seekingalpha.comBLCM Bellicum Pharmaceuticals, Inc.September 1, 2022 | finance.yahoo.comBellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceAugust 25, 2022 | finance.yahoo.comBellicum Pharmaceuticals (BLCM) Could Find Support Soon, Here's Why You Should Buy the Stock NowAugust 18, 2022 | finance.yahoo.comIs Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?August 11, 2022 | finance.yahoo.comBellicum Reports Second Quarter 2022 Financial Results and Provides Operational UpdateMay 13, 2022 | seekingalpha.comBellicum Pharmaceuticals GAAP EPS of -$0.25 beats by $0.42May 13, 2022 | finance.yahoo.comBellicum Reports First Quarter 2022 Financial Results and Provides Operational UpdateMarch 24, 2022 | finance.yahoo.comBellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational UpdateFebruary 16, 2022 | benzinga.comLadenburg Thalmann Initiates Coverage On Bellicum Pharmaceuticals with Buy Rating, Announces Price Target of $5January 26, 2022 | finance.yahoo.comBellicum Pharmaceuticals to Participate in the B. Riley Securities 2022 Virtual Oncology ConferenceDecember 13, 2021 | finance.yahoo.comBellicum Regains Compliance with Nasdaq Continued Listing RequirementsDecember 10, 2021 | finance.yahoo.comSumitovant Biopharma Highlights Significant Clinical, Regulatory and Commercial Achievements Across its Portfolio of Companies in the Second Quarter of FY2021December 7, 2021 | msn.comBellicum Secures $35M Via Equity Funding, Posts Interim Data From Early GoCAR-T Cancer StudiesDecember 6, 2021 | markets.businessinsider.comBellicum Reports Positive Interim Data From Phase 1/2 GoCAR-T Trials - Quick FactsDecember 6, 2021 | finance.yahoo.comBellicum Announces Positive Interim Data from Phase 1/2 GoCAR-T® Studies, Secures $35 Million Private Placement Equity Financing Priced at MarketDecember 2, 2021 | bizjournals.comK2 BioLabs hiring, expanding contract research offerings for biotech, pharma startupsNovember 4, 2021 | finance.yahoo.comBellicum Reports Third Quarter 2021 Financial Results and Provides Operational UpdateSeptember 3, 2021 | finance.yahoo.comBellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment ConferenceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BLCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bellicum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address BLCM Company Calendar Last Earnings11/10/2022Today2/02/2023Next Earnings (Estimated)3/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BLCM CUSIPN/A CIK1358403 Webwww.bellicum.com Phone(281) 454-3424FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.00 High Stock Price Forecast$5.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+323.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,700,000.00 Net MarginsN/A Pretax Margin-1,082.27% Return on Equity-140.56% Return on Assets-55.50% Debt Debt-to-Equity RatioN/A Current Ratio5.44 Quick Ratio5.44 Sales & Book Value Annual Sales$6.20 million Price / Sales1.64 Cash FlowN/A Price / Cash FlowN/A Book Value$2.90 per share Price / Book0.41Miscellaneous Outstanding Shares8,610,000Free Float7,726,000Market Cap$10.16 million OptionableOptionable Beta1.56 Key ExecutivesRichard A. FairPresident, Chief Executive Officer & DirectorJenny ChaplinVice President-Strategic OperationsJoseph Howard SenesacSenior VP-Technical Operations & QualityJ. Henri BayleVice President-ResearchCharity ScriptureChief Development OfficerKey CompetitorsKintara TherapeuticsNASDAQ:KTRAXenetic BiosciencesNASDAQ:XBIOAgile TherapeuticsNASDAQ:AGRXCingulateNASDAQ:CINGVirpax PharmaceuticalsNASDAQ:VRPXView All Competitors BLCM Stock - Frequently Asked Questions Should I buy or sell Bellicum Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bellicum Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BLCM shares. View BLCM analyst ratings or view top-rated stocks. What is Bellicum Pharmaceuticals' stock price forecast for 2023? 1 analysts have issued 12 month price targets for Bellicum Pharmaceuticals' shares. Their BLCM share price forecasts range from $5.00 to $5.00. On average, they expect the company's share price to reach $5.00 in the next year. This suggests a possible upside of 323.7% from the stock's current price. View analysts price targets for BLCM or view top-rated stocks among Wall Street analysts. How have BLCM shares performed in 2023? Bellicum Pharmaceuticals' stock was trading at $0.72 at the beginning of the year. Since then, BLCM stock has increased by 63.9% and is now trading at $1.18. View the best growth stocks for 2023 here. When is Bellicum Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023. View our BLCM earnings forecast. How were Bellicum Pharmaceuticals' earnings last quarter? Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) posted its quarterly earnings results on Thursday, November, 10th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter. The biopharmaceutical company had revenue of $1 million for the quarter. When did Bellicum Pharmaceuticals' stock split? Shares of Bellicum Pharmaceuticals reverse split on Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 5th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Bellicum Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Alliance Resource Partners (ARLP), AVEO Pharmaceuticals (AVEO), TransEnterix (TRXC), CyberArk Software (CYBR), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Novavax (NVAX), Pfizer (PFE) and Inovio Pharmaceuticals (INO). When did Bellicum Pharmaceuticals IPO? (BLCM) raised $101 million in an initial public offering on Thursday, December 18th 2014. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray acted as the underwriters for the IPO and Trout Capital was co-manager. What is Bellicum Pharmaceuticals' stock symbol? Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM." Who are Bellicum Pharmaceuticals' major shareholders? Bellicum Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Bellicum Pharmaceuticals? Shares of BLCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Bellicum Pharmaceuticals' stock price today? One share of BLCM stock can currently be purchased for approximately $1.18. How much money does Bellicum Pharmaceuticals make? Bellicum Pharmaceuticals (NASDAQ:BLCM) has a market capitalization of $10.16 million and generates $6.20 million in revenue each year. The biopharmaceutical company earns $-9,700,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. How can I contact Bellicum Pharmaceuticals? Bellicum Pharmaceuticals' mailing address is 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030. The official website for the company is www.bellicum.com. The biopharmaceutical company can be reached via phone at (281) 454-3424 or via email at robert.uhl@westwicke.com. This page (NASDAQ:BLCM) was last updated on 2/3/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.